Professor Ahmad Awada studied Medicine at the Université Libre de Bruxelles (ULB), Belgium. He did a specialisation in Internal Medicine and Medical Oncology at Jules Bordet Institute (under the supervision of Professor Jean Klastersky), in Brussels, until 1992 (“La plus grande distinction”). During his specialisation, he also followed trainings in the clinical development of new therapies and new anticancer drugs, mainly in breast cancer under the supervision of Professor Martine Piccart.
To deepen his training, he stayed in the Netherlands (New Drug Development Office, Free University, Amsterdam) and in San Antonio, USA (Institute for Drug Development, under the direction of Professor D. Von Hoff). He focused on the clinical development of new anticancer agents in solid tumors.
Back from the USA at the beginning of 1994, Doctor Awada became Assistant Head of Medical Oncology Clinic, and Head of the New Drugs Development Unit at Jules Bordet Institute, Brussels. Since April 2005, he is the Head of the Medical Oncology at Jules Bordet Cancer Institute. In addition and from 7th July 2017, Dr Awada was held Head of Oncology Medicine Department. He has an important clinical activity in the treatment of solid tumors. Doctor Awada took an active part in the development of new drugs (cytotoxics, molecular-targeted therapies, immunotherapy), some of them already widely used.
Thanks to the progress in technology and computer sciences, and consequently in molecular biology, we can understand better now the biology of cancer. Many drugs are now studied to block this process. Those are the molecular-targeted therapies, a subject studied extensively in clinical research by Doctor Awada and were the basis for this thesis obtained from the ULB, Brussels, in 2004.
The aim of Doctor Awada, as far as research is concerned, is to look for new active anticancer drugs in solid tumors (new cytotoxics, molecular targeted therapies, immunotherapy), and to individualize the treatments of cancer patients.
Certificate of competence in Medical Oncology (Grande distinction) 1992 - ULB
Certificate of competence in electrocardiography 1987 - ULB
Certificate of GCP training course (2012-2016)
Prix de la fondation "Marc Hurard" consacré pour l’année 1996 à la recherche médicale et pharmacologique dans le domaine de la cancérologie.
Prix de la fondation "Docteur Maurice Godin-Maria Savelkoul" (période 1998-2000) de l'académie royale de Médecine pour l'activité de recherche clinique pour le développement de nouveaux agents anticancéreux.
Brevet « de distinction honorifique dans les ordres nationaux », Belgium (2014)
Prix Fonds Gaston Ithier pour le projet « Plateforme de recherche clinique et transrationnelle pour l’optimisation de la prise en charge diagnostique et thérapeutique des métastases cérébrales (2018)
Society, organizations and committee memberships, editorial members of scientific journals and reviewers of scientific journals:
European Organisation for Research and Treatment of Cancer (EORTC)
President of the EORTC-IDMC (2013 – 2015)
Phase I-II expert of the EORTC protocol review committee (2003-2017)
Alex De Caluwé, M.D., is a radiation oncologist at the Jules Bordet Institute and at AZ St Maarten.
Earning his medical degree and radiation oncology qualifications at the University of Leuven (KU Leuven), he completed a fellowship in advanced radiotherapy techniques at the BC Cancer Agency in British Colombia (Canada) and joined the Jules Bordet Institute in 2015.
He is currently pursuing a Ph.D. in the field of innovative neo-adjuvant radiotherapy-immunotherapy combinations in breast cancer under direction of Prof. Piccart, Prof. Ignatiadis and Prof. Poortmans. As a radiation oncologist, he has a special interest in breast cancer, SBRT and gynecologic brachytherapy.
Publicaties van DE CALUWE Alex, MD
Presentations by DE CALUWE Alex, MD at the annual meeting
Hannelore Denys, MD, PhD, is a medical oncologist at the University Hospital of Gent.
Hannelore completed her medical degree in 1997 at the University of Gent. During her specialization in Internal Medicine at her Alma Mater, she was awarded with a scholarship as ‘aspirant’ of the ‘Nationaal Fonds voor Wetenschappelijk Onderzoek’ (FWO) and obtained her PhD in Biomedical Sciences at the Catholic University of Leuven (2003). She completed her medical oncology training in 2005 and has been working at the department of Medical Oncology, University Hospital of Gent since then.
Already during her training, she developed an early interest in women cancers and after graduation she focused her clinical career towards breast- and gynecological cancers. Her mission is contributing to better outcome for patients with breast- and gynecological cancers through translational driven clinical trials. She is principal or co-investigator of several phase II, III and IV clinical trials.
Besides her clinical dedication towards breast cancer, she is also involved in translational research. Under her supervision, four PhD students are currently performing research projects concerning breast cancer. She is promotor or co-promotor of several research grants from “Kom Op Tegen Kanker” and FWO.
She is a (board)member of ESMO, BSMO, ESGO, EORTC and BGOG. From January 2018, she is chairmen of the Biomedical Commission of “Kom Op Tegen Kanker”.
Publicaties van DENYS Hannelore, MD, PhD
Presentations by DENYS Hannelore, MD, PhD at the annual meeting
DESMEDT Christine, PhD – Translational Breast Cancer Researcher
Christine Desmedt received her bio-engineer degree in Cells and Genes Biotechnology from the KU Leuven in 2000. In September 2000, she started working at the Jules Bordet Institute, Brussels, an autonomous comprehensive cancer center devoted entirely to the fight against cancer. For two years, she worked as a clinical monitor for the Breast European Adjuvant Studies Group (Br.E.A.S.T), coordinating the monitoring activities of external groups for the conduct of breast cancer trials. This experience gave her the necessary clinical background for carrying optimal translational breast cancer research.
In 2003, she joined the Breast Cancer Translational Research Laboratory of this Institute, headed by Prof. Christos Sotiriou, where she started a PhD entitled “Multimarker approach for improving breast cancer treatment tailoring” with Prof. Martine Piccart as co-promoter. In 2004, she earned a master in bio-medical sciences at the Université Libre de Bruxelle (U.L.B.) and defended successfully her PhD in 2008. Until 2018, she acted as the Translational Research Coordinator of the lab, conducting research projects and assisting the head of the lab in the scientific and administrative management of the lab. From October 2010 till April 2011, she was a visiting scientist at the Wellcome Trust Sanger Institute, Hinxton, UK, under the supervision of Dr. P. Campbell in the Cancer Genome Project lab. This allowed her to have a detailed introduction to next generation sequencing and to develop important collaborations in the field of genomics and cancer.
In October 2018, Christine Desmedt was appointed as Assistant Professor at the Katholieke Universiteit Leuven (KU Leuven, Leuven), where she is heading the Laboratory for Translational Breast Cancer Research. The main research areas of the Lab are the molecular characterization of breast cancer, including the unraveling of metastatic progression, the better understanding of rarer cancer subtypes such as lobular and mucinous breast tumors, the identification of mechanisms of treatment efficacy and the impact of patient adiposity on breast cancer biology. She is also the co-leader of the Breast Cancer group of the Leuven Cancer Institute (LKI) with Prof. Dr. Hans Wildiers. She is also co-developer and co-leader of the breast cancer research autopsy program at UZ/KU Leuven with Prof. Dr. Giuseppe Floris. Prof. Desmedt is very active in lobular breast cancer research. She is the co-founder and co-coordinator of the European Lobular Breast Cancer Consortium (www.elbcc.org) together with Prof. P. Derksen (University of Utrecht, The Netherlands) and Prof. Dr. A. Salomon (Institut Curie, Paris, France), and the vice-president of the COST Action CA 19138 LOBSTERPOT, entirely devoted to lobular breast cancer research. She is also co-coordinator of the Doctoral School Cancer at the KU Leuven.
Prof. Desmedt authored >100 peer-reviewed publications, of which 30 as main author and 14 as corresponding author (H-index=56, total citations>23,000, Google Scholar November 2020).
Publicaties van DESMEDT Christine, PhD
Presentations by DESMEDT Christine, PhD at the annual meeting
Johnny Duerinck, MD, PhD, is neurosurgeon and clinical researcher at the University Hospital Brussels (Uz Brussel) and professor of neurosurgery at the Vrije Universiteit Brussel (VUB). He graduated from medical school at the VUB in 2007 and became neurosurgeon at Uz Brussel in 2013. His training in neurosurgery was marked by a special interest in neuro-oncology, which is the field where he completed his PhD in 2017. He is a member of the EORTC Brain Tumor group (BTG) as well as a board member of the Belgian Association of Neuro-Oncology (BANO).
As a neurosurgeon, his main clinical focus is on the full scope of neuro-oncology, including both surgical and non-surgical treatment of brain tumors. He spent several time periods in foreign centers in Montpellier and Milan to learn techniques that are used to operate brain injuries that are located near functionally important brain zones. He is also interested in complex spinal neurosurgery using both minimally invasive and open techniques.
His clinical research in neuro-oncology is performed in collaboration with Prof Bart Neyns and currently focused on immune therapy for brain tumors and innovative ways of peroperatively and postoperatively administering immunotherapeutic agents.
He also has a special long-standing interest in new technologies and their application in health care, culminating in a parallel research line looking at implementing augmented and virtual reality and artificial intelligence into daily neurosurgical practice.
Publicaties van DUERINCKX Johnny, MD, PhD
Presentations by DUERINCKX Johnny, MD, PhD at the annual meeting
DUHEM Caroline, MD – Internal Medicine – Medical Oncology
Caroline Duhem is Director of the Kriibszentrum, CHL Luxembourg. She earned her medical degrees and oncology qualifications at UCL.
She is member of the Société Luxembourgeoise d’Oncologie (SLO), SLO delegated member in Breast International Group (BIG), member of the Belgian Society of Medical Oncology (BSMO), board member of the Société Belge de Sénologie (SBS-BVS), member of the European Society of Medical Oncology (ESMO), member of the Oncodistinct Network.
In parallel to her clinical and scientific activities, she is actively implicated in creation and development of supportive structures dedicated to patients quality of life: Integrative oncology to breast cancer patients, prehabilitation and rehabilitation programs , Oncofertility national network, Association des Groupes sportifs Oncologiques (ALGSO).
Publicaties van DUHEM Caroline, MD
Presentations by DUHEM Caroline, MD at the annual meeting
DUHOUX Francois, MD, PhD – Medical Oncologist and Clinical Geneticist
Francois P Duhoux is a Professeur of Medicine at UCLouvain, where he lectures on the medical management of breast cancer and hereditary cancer predisposition syndromes.
He is a medical oncologist and clinical geneticist at Cliniques universitaires Saint-Luc in Brussels, where he specializes in the care of patients with breast cancer and the management of hereditary breast and ovarian cancer. He is head of the research section within the breast cancer clinic.
Professor Duhoux completed his medical education from UCLouvain in 2004, followed by numerous specialty training posts in internal medicine and medical oncology in Belgium and in France (Institut Curie in Paris), between 2004 and 2012. He also holds a degree in oncogenetics from University Paris 7, obtained in 2011. Professor Duhoux completed his PhD in medical genetics at UCLouvain. He also obtained the Belgian Society of Human Genetics (BeSHG) Interuniversity Certificate in Human Genetics in 2012 and has expertise in hereditary cancer predisposition syndromes.
Professor Duhoux is currently the principal investigator for over 30 phase I, II, and III clinical trials in breast cancer. He is the president of the Belgian Society of Senology (SBS/BVS) and a member of the American Society of Clinical Oncology (ASCO), European Society for Medical Oncology, Belgian Society of Medical Oncology, American Association for Cancer Research (AACR), and Belgian Society of Human Genetics. Professor Duhoux authored over 50 manuscripts in peer-reviewed journals, and has presented at numerous international congresses, including the ASCO Annual Meeting and the San Antonio Breast Cancer Symposium (SABCS).
Publicaties van DUHOUX Francois, MD, PhD
Presentations by DUHOUX Francois, MD, PhD at the annual meeting
Guy Jerusalem, MD, PhD, is head of Medical Oncology at the Sart-Tilman University Hospital and Professor in Medical Oncology at the University of Liège. Prof. Jerusalem is director of the Breast Clinic in his hospital. Prof. Jerusalem received his medical and doctoral degrees from University of Liège.
Prof. Jerusalem is member of the Executive of the Scientific Committee and member of the Foundation Council of the International Breast Cancer Study Group (IBCSG). He is head of the Clinical Research Unit of the department of Medical Oncology at the University Hospital of Liège.
Prof. Jerusalem is member of the Writing Committee of the CONFIRM trial, member of the Steering Committee of several large international trials including SOLE, Bolero 3, Aphinity, SNAP, Bolero 6, Monaleesa 3, PALLAS, ALEXANDRA/Impassion 030, SAKK 21/18, CA209-7A8, EPIK-B2 - CBYL719G12301 and coordinating physician of the ixabepilone Drug Response Prediction trial.
Prof. Jerusalem holds ESMO certification in Medical Oncology.
He is a member of the American Society of Clinical Oncology, the European Society of Medical Oncology, and the Belgian Society of Medical Oncology.
Prof. Jerusalem has co-authored 11 book chapters and has published widely in journals such as NEJM, Lancet Oncology, JAMA Oncology, Nature, J Natl Cancer Inst, Journal of Clinical Oncology, Blood, The Oncologist, Annals of Oncology, Clinical Cancer Research, Cancer Research, Breast Cancer Research and Treatment and European Journal of Cancer. He is author or co-author of over 200 publications referenced in Pub Med.
Publicaties van JERUSALEM Guy, MD, PhD
Presentations by JERUSALEM Guy, MD, PhD at the annual meeting
Martine J. Piccart, M.D., Ph.D., is honorary professor of oncology at the Université Libre de Bruxelles (ULB) and scientific director at the Jules Bordet Institute (Brussels/Belgium). Earning her medical degrees at ULB and oncology qualifications in New York and London, she is also a member of the Belgian Royal Academy of Medicine. She held presidencies of the European CanCer Organisation (ECCO), the European Organisation for the Research and Treatment of Cancer (EORTC), the European Society for Medical Oncology (ESMO). She served on the American Society of Clinical Oncology Board (ASCO) as well as on the Board of the American Association for Cancer Research (AACR) which nominated her as fellow of the AACR Academy in 2013.
A strong advocate for and leader of international research collaborations, Prof. Martine Piccart, together with Prof. Aron Goldhirsch, created the Breast International Group (BIG) in 1996 to foster collaboration and accelerate the development of better breast cancer treatments. The organisation, chaired by Prof. Piccart, became an international not-for-profit organization in 1999, and today unites 59 academic breast cancer research groups from around the world. BIG has more than 30 clinical trials under its umbrella at any one time, and several of BIG’s past studies are considered landmark and practice-changing.
Prof. Piccart’s relentless drive for results has made her an international leader, who has forged collaborations all over the world and has successfully managed a number of high-profile, Phase 3 clinical trials that have involved multiple international investigators and institutions. Those clinical trials include HERA (HERceptin Adjuvant), MINDACT (Microarray In Node-Negative and 1 to 3 Positive Lymph Node Disease May Avoid Chemotherapy), and ALTTO (Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation).
In 2014, BIG launched AURORA, an innovative molecular screening programme aiming to understand the molecular aberrations driving breast cancer metastasis and why tumours respond differently to therapy. Over 80 hospitals associated with 10 BIG research groups in 11 countries are taking part. Prof. Piccart believes this type of research will enable much more effective treatment of metastatic breast cancer in the future.
Throughout her career, Prof. Piccart has been honoured with numerous prestigious awards for her research contributions, including the Jill Rose Award for distinguished biomedical research (2009, New York, USA), the William L. McQuire Award in recognition of her contribution in breast cancer research (2009, SABCS, San Antonio/Texas, USA), the Umberto Veronesi Award for the Future Fight Against Cancer (2012, Cancun, Mexico), the David A. Karnofsky Memorial Award in recognition of innovative clinical research and developments that have changed the way oncologists think about the general practice of oncology (2013, ASCO, Chicago, USA), the Susan G. Komen’s Brinker Award for Scientific Distinction (2015, SABCS, San Antonio/Texas, USA) and, the 2017 St. Gallen International Breast Cancer Award and most recently, the 2018 Prix Leopold Griffuel for translational and clinical research delivered by the “Association pour la Recherche sur le Cancer” in France and the KNAW Bob Pinedo Cancer Care Award in November 2018 in Amsterdam, Netherlands.
An accomplished clinician and scientist, Prof. Piccart is author or co-author of over 530 publications in peer-reviewed journals.
Publicaties van PICCART Martine, MD, PhD
Presentations by PICCART Martine, MD, PhD at the annual meeting
Kevin Punie is a medical oncologist working as a staff member at the department of General Medical Oncology in the University Hospitals Leuven, Belgium. His main areas of interest are breast cancer and hereditary cancer syndromes.
He is deeply involved in clinical cancer research as principal investigator for several phase I-III trials with a focus on triple negative breast cancer. He is currently working on a PhD on plasma metabolomics in breast cancer.
He is involved in the EORTC Breast Cancer Group, board member of the Belgian Society of Medical Oncology and Committee member of ESMO Young Oncologists Committee and ESMO Resilience Task Force.
Publicaties van PUNIE Kevin, MD
Presentations by PUNIE Kevin, MD at the annual meeting
REMOUCHAMPS Vincent, MD – Radiation Oncologist
Graduated in medicine in 1993, Vincent Remouchamps completed 3 years of specialization in internal medicine before specializing in Radiotherapy -Oncology at UCL with Professor Scalliet (3 years) and in Ghent with Professor De Neve (1 year), followed by 2 years of fellowship in the United States in William Beaumont Hospital, a pioneering center for several domains of Radiotherapy such as breathing control and Image Guided Radiotherapy.
Full-time radiotherapist-oncologist in Namur since 2003, he focuses on the field of breast, lung and hematological cancers. Besides his career as mainly a clinician, he maintains interest in academic activities, with the (co) -publication of 35 peer-reviewed articles, more congress abstracts, the pursuit of collaborative developments and the interest in the collaboration of national and international multicenter studies, in parallel with the current management of the department and the supervision of trainees.
Publicaties van REMOUCHAMPS Vincent, MD
Presentations by REMOUCHAMPS Vincent, MD at the annual meeting
VANHOEIJ Marian, MD – Surgical Oncology
Marian Vanhoeij is guest professor of surgery at VUB (Vrije Universiteit Brussel). She earned her medical and surgical degree at VUB in 2000 en 2006. In 2019 she became the Breast Clinic Coördinator as well as the coordinating surgical trainer for VUB/UZ Brussel.
As surgeon, she is specifically interested in oncoplastic surgery as well as surgical de-escalation by avoiding unnecessary surgery. Scientifically, her research domain is the use of immunotherapy in early breast cancer.
She is an active member of the Belgian Society of Breast Surgeons.
Publicaties van VANHOEIJ Marian, MD
Presentations by VANHOEIJ Marian, MD at the annual meeting
Hans Wildiers is a medical oncologist dedicated to breast cancer research. He is staff member at the department of medical oncology in the University Hospital Leuven, Belgium since 2004. He coordinates the Leuven multidisciplinary breast center since 2015.
He has been coordinator of several academic studies in the field of breast cancer and geriatric oncology, and author of more than 250 peer reviewed papers.
He has been active within the board of SIOG, the international society of geriatric oncology, for many years, and served this organization as president from 11-2018 till 10-2020. From 2009 till 2015, he has chaired the elderly task force cancer of the European Organization of Research and Treatment of Cancer (EORTC).
Publicaties van WILDIERS Hans, MD, PhD
Presentations by WILDIERS Hans, MD, PhD at the annual meeting